Jake King, Editor
Mr. King brings four years of investigative journalism experience, covering financial and broader economic policies affecting investment and growth. Previously Mr. King worked for a non-profit 501(c)(3) organization based in Washington, D.C., where his responsibilities included facilitating communications between private entities vying for grants and federal bodies distributing subsidies. Mr. King graduated with a B.A. in English and Writing from Eastern Mennonite University, where he was Editor-In-Chief of the widely-read university newspaper, The Weathervane.
Dee Kotak, MD, Contributor
Dr. Kotak is currently an investment manager for a small healthcare private equity firm and chief medical officer of a medical device company. He brings over 20 years of experience in hospital medicine as a physician and has also practiced as an attorney. Dee has been an investor in life science companies for over a decade and has a particular interest in emerging science and technology. He graduated with an MA from Oxford University and an MD from the University of London.
Jason Napodano, CFA, Contributor
Jason Napodano is the Managing Director for the U.S. Institutional Equity Research Division for Zacks. Jason has been with Zacks Investment Research since 2003 working as the Senior Pharmaceutical & Biotechnology analyst. Before joining Zacks, Jason Napodano served as Vice President and Senior Equity Analyst covering U.S. large-cap equities for Eastover Capital Management from 1999 to 2002. Prior to Eastover, Jason worked as a laboratory research scientist for TechLab Inc., a biotechnology company focused on the development of diagnostic kits and vaccines for infectious disease, from 1995 to 1998. Jason holds a BS from Virginia Tech in Biochemistry and a MBA from Wake Forest University. Jason is also a Chartered Financial Analyst.
Ivan Deryugin, Contributor
Mr. Deryugin is the founder of Helix Investment Management, founded in July 2011 as an investment management and advisory firm. Helix and Mr. Deryugin tend to take a secular, thesis based approach to investing, looking for fundamental trends around the globe that transcend the vagaries of the business cycle. Ivan’s work is regularly featured on Seeking Alpha and other prominent financial websites.
Rajesh Patel, Ph.D., Contributor
Rajesh is the Managing Director for Equities at Red Acre Investments, where he leads the firm in researching and executing trades. Red Acre specializes in binary events, special situations, and mispriced securities, and in 2012 the firm realized trading gains of 699% due to Rajesh’s leadership. Prior to Red Acre, Rajesh was a Member of Technical Staff with the Massachusetts Institute of Technology, (MIT) Lincoln Laboratory where he analyzed the strategic value of emerging technologies to enhance the capabilities of the U.S. Military. Rajesh holds a Ph.D. in Applied Physics from the University of California, Davis, a Master’s in Environmental Science from Rice University, and bachelors degrees in both Physics and English from the University of Connecticut.
Aafia Chaudhry, MD, Contributor
Dr. Chaudhry is a founding partner at Noesis LLC, an investment management firm focused on the pharmaceutical and biotechnology sectors. She is a graduate of the University of Manchester Medical School and originally trained in general surgery prior to transitioning her career into the healthcare industry. Aafia has been an active life sciences investor for the past eight years and is an expert in pharmaceutical life cycle management strategy. She was formerly President of 81qd, a strategic data analytics consultancy, and most recently was VP, Strategic Market Planning at WebMD Health Corp.
As we observe intriguing developments or technical news we publish our analysis and thoughts collectively under Editorial Staff. Articles by Editorial Staff is simply the culmination of due diligence by several members of our research team.
PropThink continues to search for individuals with a strong background researching and analyzing emerging growth healthcare companies to join our organization on a full-time or contract basis. If this is you, please contact us.